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Introduction: Malignant afferent loop obstruction following pancreaticoduodenectomy is a rare complication and
may be fatal if suppurative cholangitis or obstructive jaundice develops. Effective and safe therapeutic strategies for
malignant afferent loop obstruction following pancreaticoduodenectomy are scarce at present.
Case presentation: A 51-year-old Japanese man underwent pancreaticoduodenectomy for carcinoma of the
papilla of Vater. Seven months postoperatively, he developed a high-grade fever, jaundice, and right upper
abdominal pain. Abdominal contrast-enhanced computed tomography showed afferent loop obstruction and
intrahepatic bile duct dilatation due to nodal recurrence. Percutaneous transhepatic biliary drainage was performed,
and a self-expanding metallic stent (WallFlex™ duodenal stent) was placed across the stricture using the
transhepatic route.
Conclusions: There are surgical and nonsurgical treatments for malignant afferent loop obstruction following
pancreaticoduodenectomy. Nonsurgical treatments include either an endoscopic or percutaneous approach to the
afferent loop. Of these methods, percutaneous transhepatic insertion of a self-expanding metallic stent is the
preferred treatment for malignant afferent loop obstruction following pancreaticoduodenectomy because it is more
prompt and less invasive.
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Afferent loop obstruction following pancreaticoduodenect-
omy (PD) is a rare complication. Most cases of afferent
loop obstruction following PD are malignant and may be
fatal if cholangitis or jaundice develops [1-4]. Malignant af-
ferent loop obstruction following PD presents a particular
therapeutic challenge because the postsurgical anatomy
usually prevents an endoscopic approach [2,5]. However,
appropriate therapeutic strategies for malignant afferent
loop obstruction following PD are scarce at present. We
recently experienced a case of malignant afferent loop
obstruction following PD treated with percutaneous* Correspondence: i-hosokawa@umin.ac.jp
Department of General Surgery, Chiba University Graduate School of
Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
© 2012 Hosokawa et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumtranshepatic insertion of a self-expanding metallic stent
(WallFlex™ duodenal stent), and we herein present this
case.Case presentation
A 51-year-old Japanese man underwent PD with Child re-
construction and Braun anastomosis for T4 N2 carcinoma
of the papilla of Vater. Four of 34 resected lymph nodes
were involved, but an R0 resection margin was achieved.
Adjuvant chemotherapy with S-1 (tegafur-gimeracil-oteracil
potassium) was performed after surgery. Seven months
postoperatively, he developed a high-grade fever, jaundice,
and right upper abdominal pain. The laboratory data on ad-
mission were as follows: white blood cell count, 9900/mm3;
total bilirubin, 22.7mg/dL; aspartate aminotransferase,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ical diagnosis was suppurative cholangitis and obstructive
jaundice. Abdominal enhanced computed tomography
(CT) showed afferent loop obstruction and intrahepatic bile
duct dilatation caused by nodal recurrence (Figure 1). To
relieve jaundice and prevent cholangitis, ultrasound-guided
percutaneous transhepatic biliary drainage was performed
under local anesthesia. A 7 French pigtail catheter was
inserted into the afferent loop from the tributary of seg-
ment three (Figure 2a). The guide wire was then advanced
into the proximal aspect of the obstruction, and an 8
French straight endoprosthesis catheter was inserted
(Figure 2b). The catheter was dilated from 8 to 12 French
to deliver the self-expanding metallic stent. Jejunography
confirmed an approximately 4 cm-long stricture of the af-
ferent loop (Figure 3a), and a 22mm×12cm self-
expanding metallic stent (WallFlex™ duodenal stent, Bos-
ton Scientific) was placed across the stenosis via the trans-
hepatic route (Figure 3b). On stent placement, we used
the straight guide wire which was 0.035 inches in diameter
and 450cm length. The next day, the expansion of the
stent was good and balloon expansion was not needed.
There were no procedural complications. His jaundice
rapidly disappeared, and clinical conditions quickly
improved. His hospital stay was 17 days. Stent patency
was good, and cholangitis did not recur during five
months of follow-up. He is currently receiving chemother-
apy with gemcitabine as an outpatient.Discussion
Afferent loop obstruction is an unusual but serious
complication following Billroth II gastrojejunostomy.
Most cases are caused by benign obstruction of the af-
ferent loop from an internal hernia, kinking at the anas-
tomosis, or inflammation surrounding the anastomosis.a
b
Figure 1 Abdominal contrast-enhanced computed tomography on ad
showed afferent loop obstruction and intrahepatic bile duct dilatation dueMalignant occlusion is rare and generally caused by re-
current tumors or metastasis [3]. Obstruction of the af-
ferent loop with ongoing accumulation of biliary,
pancreatic, and intestinal secretions results in afferent
bowel dilatation and subsequent biliary dilatation. Most
of the clinical findings of afferent loop obstruction are
relatively nonspecific and include abdominal pain, nau-
sea and vomiting, fever, and obstructive jaundice. Al-
most all reported cases of afferent loop obstruction
following PD involve malignant disease because of the
high biological malignancy of the diseases for which PD
is performed [2,6]. Afferent loop obstruction following
PD easily results in cholangitis or jaundice because of
the abolition of papillary functions [1-4]. Therefore, less
invasive treatment for recurrent disease and immediate
treatment for cholangitis or jaundice are required.
In the past, the incidence of afferent loop obstruction
following PD was very rare. However, Pannala et al. [7]
reported that the incidence of afferent loop syndrome
following PD for pancreatic carcinoma was 13%, and
survival of two years or longer was the only factor asso-
ciated with the development of afferent limb syndrome.
Recently, survival of pancreatic cancer has been
extended due to the development of adjuvant chemo-
therapy. Therefore, the incidence of afferent loop ob-
struction following PD may be increased in the future.
We reported a successful outcome of percutaneous
transhepatic insertion of a self-expanding metallic stent
for malignant afferent loop obstruction following PD in
a patient who was too unwell to undergo surgery and in
whom the peroral approach could not be used because
of altered upper gastrointestinal tract anatomy.
There are several treatments for malignant afferent
loop obstruction following PD (Table 1). Surgery is ef-
fective but largely invasive [1]. Many patients with ma-
lignant upper gastrointestinal obstructions are not wellmission. Abdominal contrast-enhanced computed tomography
to nodal recurrence (white arrow).
a b
Figure 2 Percutaneous transhepatic biliary drainage for treatment of malignant afferent loop obstruction. (a) A 7 French pigtail catheter
was inserted into the afferent loop from the tributary of segment 3. (b) The guide wire was advanced into the proximal aspect of the
obstruction, and an 8 French endoprosthesis catheter was inserted.
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resection is usually impossible, and these patients are
treated with jejunojejunostomy or Roux-en-Y bypass [8].
Surgical procedures are often difficult because of intra-
abdominal adhesion and tumor infiltration and cause
significant morbidity and mortality despite a short life
expectancy [1]. Therefore, nonsurgical alternatives are
clearly desirable [1].
An endoscopic approach to the afferent loop is less in-
vasive, but is usually difficult because of postoperative
anatomic changes [2,5]. Because of the high degree of af-
ferent loop stenosis by the time patients develop symp-
toms such as jaundice, endoscopic treatment is mostly
impossible [1]. The use of double-balloon endoscopy to
approach the afferent loop in patients with surgicallya
Figure 3 Stent placement. (a) Jejunography confirmed an approximately
self-expanding metallic stent was placed across the stenosis via the transhealtered anatomy was recently shown to be safe and feas-
ible [4,9]. A double-balloon endoscopic approach might
be considered in selected patients with afferent loop
obstruction.
Direct percutaneous puncture to the afferent loop is
possible if the distended afferent loop underlies the anter-
ior abdominal wall [1]. However, this procedure is compli-
cated and there is a risk of bile leakage and subsequent
peritonitis because the loop may decompress and collapse
after puncture [2]. Therefore, it is necessary to fix the af-
ferent loop to the anterior abdominal wall as well as per-
form gastrostomy to prevent peritoneal leaks [2].
The transhepatic route is effective and less invasive for
initial treatment for cholangitis or jaundice. This route
can also estimate the bilioenteric anastomosis patencyb
4cm-long stricture of the afferent loop. (b) A 22mm×12cm
patic route.
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patients with afferent loop symptoms without jaundice
or dilation of intrahepatic biliary ducts.
In the present case, we chose the percutaneous trans-
hepatic route for prompt treatment of severe cholangitis
and jaundice. At the same time, we confirmed bilioen-
teric anastomosis patency. Because the stricture of the
afferent loop was readily accessible by the transhepatic
route, we naturally used this route for stent placement.
We consider that this is a very simple and natural pro-
cedure to treat malignant afferent loop obstruction fol-
lowing PD with cholangitis or jaundice. There are
several reports in which a 10mm biliary stent was used
for the relief of malignant afferent loop obstruction.
However, narrow biliary stents have a high risk of tumor
ingrowth and occlusion. Moreover, biliary stents are
more likely to migrate within the larger lumen of the
small bowel. In this case, we chose a 22mm duodenal
stent with a flare, which reduced the risk of migration
and occlusion. Duodenal stents may be available with
endoscopic (“through-the-scope”, or “TTS”) delivery sys-
tems, which are mostly 10 French. Thus, this stent can
usually be advanced through the liver without too much
difficulty.
Survival of patients who undergo metallic stent inser-
tion for malignant afferent loop obstruction is likely to
increase even further with improvements in palliative
chemotherapy regimens [2]. Therefore, maintenance of
stent patency is an important factor following stent in-
sertion. The use of duodenal instead of biliary stents will
delay reocclusion by tumor growth and should be con-
sidered to be the devices of choice.Conclusions
Several treatment modalities for afferent loop obstruction
following PD exist, each with specific merits and draw-
backs. Although treatment should be appropriate to indi-
vidual cases, percutaneous transhepatic insertion of a self-
expanding metallic stent is the preferable treatment for
malignant afferent loop obstruction following PD because
it is prompt and less invasive.Consent
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for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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